Blockade of PD‐1 or p38 MAP kinase signaling enhances senescent human CD8+ T‐cell proliferation by distinct pathways

Immune enhancement is desirable in situations where decreased immunity results in increased morbidity. We investigated whether blocking the surface inhibitory receptor PD‐1 and/or p38 MAP kinase could enhance the proliferation of the effector memory CD8+ T‐cell subset that re‐expresses CD45RA (EMRA)...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of immunology Vol. 45; no. 5; pp. 1441 - 1451
Main Authors Henson, Sian M., Macaulay, Richard, Riddell, Natalie E., Nunn, Craig J., Akbar, Arne N.
Format Journal Article
LanguageEnglish
Published Germany Wiley Subscription Services, Inc 01.05.2015
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Immune enhancement is desirable in situations where decreased immunity results in increased morbidity. We investigated whether blocking the surface inhibitory receptor PD‐1 and/or p38 MAP kinase could enhance the proliferation of the effector memory CD8+ T‐cell subset that re‐expresses CD45RA (EMRA) and exhibits characteristics of senescence, which include decreased proliferation and telomerase activity but increased expression of the DNA damage response related protein γH2AX. Blocking of both PD‐1 and p38 MAPK signaling in these cells enhanced proliferation and the increase was additive when both pathways were inhibited simultaneously in both young and old human subjects. In contrast, telomerase activity in EMRA CD8+ T cells was only enhanced by blocking the p38 but not the PD‐1 signaling pathway, further indicating that nonoverlapping signaling pathways were involved. Although blocking p38 MAPK inhibits TNF‐α secretion in the EMRA population, this decrease was counteracted by the simultaneous inhibition of PD‐1 signaling in these cells. Therefore, end‐stage characteristics of EMRA CD8+ T cells are stringently controlled by distinct and reversible cell signaling events. In addition, the inhibition of PD‐1 and p38 signaling pathways together may enable the enhancement of proliferation of EMRA CD8+ T cells without compromising their capacity for cytokine secretion.
AbstractList Immune enhancement is desirable in situations where decreased immunity results in increased morbidity. We investigated whether blocking the surface inhibitory receptor PD-1 and/or p38 MAP kinase could enhance the proliferation of the effector memory CD8(+) T-cell subset that re-expresses CD45RA (EMRA) and exhibits characteristics of senescence, which include decreased proliferation and telomerase activity but increased expression of the DNA damage response related protein γH2AX. Blocking of both PD-1 and p38 MAPK signaling in these cells enhanced proliferation and the increase was additive when both pathways were inhibited simultaneously in both young and old human subjects. In contrast, telomerase activity in EMRA CD8(+) T cells was only enhanced by blocking the p38 but not the PD-1 signaling pathway, further indicating that nonoverlapping signaling pathways were involved. Although blocking p38 MAPK inhibits TNF-α secretion in the EMRA population, this decrease was counteracted by the simultaneous inhibition of PD-1 signaling in these cells. Therefore, end-stage characteristics of EMRA CD8(+) T cells are stringently controlled by distinct and reversible cell signaling events. In addition, the inhibition of PD-1 and p38 signaling pathways together may enable the enhancement of proliferation of EMRA CD8(+) T cells without compromising their capacity for cytokine secretion.Immune enhancement is desirable in situations where decreased immunity results in increased morbidity. We investigated whether blocking the surface inhibitory receptor PD-1 and/or p38 MAP kinase could enhance the proliferation of the effector memory CD8(+) T-cell subset that re-expresses CD45RA (EMRA) and exhibits characteristics of senescence, which include decreased proliferation and telomerase activity but increased expression of the DNA damage response related protein γH2AX. Blocking of both PD-1 and p38 MAPK signaling in these cells enhanced proliferation and the increase was additive when both pathways were inhibited simultaneously in both young and old human subjects. In contrast, telomerase activity in EMRA CD8(+) T cells was only enhanced by blocking the p38 but not the PD-1 signaling pathway, further indicating that nonoverlapping signaling pathways were involved. Although blocking p38 MAPK inhibits TNF-α secretion in the EMRA population, this decrease was counteracted by the simultaneous inhibition of PD-1 signaling in these cells. Therefore, end-stage characteristics of EMRA CD8(+) T cells are stringently controlled by distinct and reversible cell signaling events. In addition, the inhibition of PD-1 and p38 signaling pathways together may enable the enhancement of proliferation of EMRA CD8(+) T cells without compromising their capacity for cytokine secretion.
Immune enhancement is desirable in situations where decreased immunity results in increased morbidity. We investigated whether blocking the surface inhibitory receptor PD‐1 and/or p38 MAP kinase could enhance the proliferation of the effector memory CD8+ T‐cell subset that re‐expresses CD45RA (EMRA) and exhibits characteristics of senescence, which include decreased proliferation and telomerase activity but increased expression of the DNA damage response related protein γH2AX. Blocking of both PD‐1 and p38 MAPK signaling in these cells enhanced proliferation and the increase was additive when both pathways were inhibited simultaneously in both young and old human subjects. In contrast, telomerase activity in EMRA CD8+ T cells was only enhanced by blocking the p38 but not the PD‐1 signaling pathway, further indicating that nonoverlapping signaling pathways were involved. Although blocking p38 MAPK inhibits TNF‐α secretion in the EMRA population, this decrease was counteracted by the simultaneous inhibition of PD‐1 signaling in these cells. Therefore, end‐stage characteristics of EMRA CD8+ T cells are stringently controlled by distinct and reversible cell signaling events. In addition, the inhibition of PD‐1 and p38 signaling pathways together may enable the enhancement of proliferation of EMRA CD8+ T cells without compromising their capacity for cytokine secretion.
Immune enhancement is desirable in situations where decreased immunity results in increased morbidity. We investigated whether blocking the surface inhibitory receptor PD-1 and/or p38 MAP kinase could enhance the proliferation of the effector memory CD8+ T-cell subset that re-expresses CD45RA (EMRA) and exhibits characteristics of senescence, which include decreased proliferation and telomerase activity but increased expression of the DNA damage response related protein [gamma]H2AX. Blocking of both PD-1 and p38 MAPK signaling in these cells enhanced proliferation and the increase was additive when both pathways were inhibited simultaneously in both young and old human subjects. In contrast, telomerase activity in EMRA CD8+ T cells was only enhanced by blocking the p38 but not the PD-1 signaling pathway, further indicating that nonoverlapping signaling pathways were involved. Although blocking p38 MAPK inhibits TNF-[alpha] secretion in the EMRA population, this decrease was counteracted by the simultaneous inhibition of PD-1 signaling in these cells. Therefore, end-stage characteristics of EMRA CD8+ T cells are stringently controlled by distinct and reversible cell signaling events. In addition, the inhibition of PD-1 and p38 signaling pathways together may enable the enhancement of proliferation of EMRA CD8+ T cells without compromising their capacity for cytokine secretion.
Immune enhancement is desirable in situations where decreased immunity results in increased morbidity. We investigated whether blocking the surface inhibitory receptor PD‐1 and/or p38 MAP kinase could enhance the proliferation of the effector memory CD8 + T‐cell subset that re‐expresses CD45RA (EMRA) and exhibits characteristics of senescence, which include decreased proliferation and telomerase activity but increased expression of the DNA damage response related protein γH2AX. Blocking of both PD‐1 and p38 MAPK signaling in these cells enhanced proliferation and the increase was additive when both pathways were inhibited simultaneously in both young and old human subjects. In contrast, telomerase activity in EMRA CD8 + T cells was only enhanced by blocking the p38 but not the PD‐1 signaling pathway, further indicating that nonoverlapping signaling pathways were involved. Although blocking p38 MAPK inhibits TNF‐α secretion in the EMRA population, this decrease was counteracted by the simultaneous inhibition of PD‐1 signaling in these cells. Therefore, end‐stage characteristics of EMRA CD8 + T cells are stringently controlled by distinct and reversible cell signaling events. In addition, the inhibition of PD‐1 and p38 signaling pathways together may enable the enhancement of proliferation of EMRA CD8 + T cells without compromising their capacity for cytokine secretion.
Author Macaulay, Richard
Nunn, Craig J.
Riddell, Natalie E.
Henson, Sian M.
Akbar, Arne N.
Author_xml – sequence: 1
  givenname: Sian M.
  surname: Henson
  fullname: Henson, Sian M.
  organization: University College London
– sequence: 2
  givenname: Richard
  surname: Macaulay
  fullname: Macaulay, Richard
  organization: University College London
– sequence: 3
  givenname: Natalie E.
  surname: Riddell
  fullname: Riddell, Natalie E.
  organization: University College London
– sequence: 4
  givenname: Craig J.
  surname: Nunn
  fullname: Nunn, Craig J.
  organization: University College London
– sequence: 5
  givenname: Arne N.
  surname: Akbar
  fullname: Akbar, Arne N.
  organization: University College London
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25707450$$D View this record in MEDLINE/PubMed
BookMark eNp9kc9u1DAQxi1URLeFI1dkiQsSSuvxnyQ-lm2Bolb0UM6R40y63mbtrZ2o7I1H4Bl5Erxs6aESnMYa_z7P5_kOyJ4PHgl5DewIGOPHuHRHnIGUSgB_RmagOBQSJOyRGcv9guua7ZODlJaMMV0q_YLsc1WxSio2I98_DMHemg5p6OnV6a8fP4GGSNeippcnV_TWeZOQJnfjzeD8DUW_MN5iogk9Jot-pItpZTydn9bv6XXWWxwGuo5hcD1GM7rgabuhnUuj83akazMu7s0mvSTPezMkfPVQD8m3j2fX88_FxddP5_OTi8JKJnghlK2FFLrECk1XydJ2Nh9lr9oWWqhUq4RmpUZha2ulzjeItgMOfVebvheH5N3u3WzpbsI0NiuXth6NxzClBsqaQVUKrTL69gm6DFPMH99SleYcdCkz9eaBmtoVds06upWJm-bvTjNQ7AAbQ0oR-0cEWLPNrMmZNY-ZZV484a0b_yxujMYN_1TxnereDbj5_4jm7Mu54JqL322Pqhs
CODEN EJIMAF
CitedBy_id crossref_primary_10_3390_ijms23137358
crossref_primary_10_3389_fimmu_2021_632667
crossref_primary_10_3390_ijms23179797
crossref_primary_10_2174_1381612825666190313115233
crossref_primary_10_3389_fimmu_2022_833531
crossref_primary_10_1016_j_ebiom_2021_103409
crossref_primary_10_1038_cmi_2017_111
crossref_primary_10_1016_j_immuni_2017_03_010
crossref_primary_10_1111_cei_12829
crossref_primary_10_3389_fimmu_2020_604591
crossref_primary_10_3389_fimmu_2018_03001
crossref_primary_10_1016_j_ctarc_2021_100494
crossref_primary_10_1016_j_celrep_2018_05_057
crossref_primary_10_1016_j_jgo_2017_02_001
crossref_primary_10_1186_s13018_025_05473_0
crossref_primary_10_1002_cti2_1091
crossref_primary_10_1002_jcp_26956
crossref_primary_10_1111_cei_13189
crossref_primary_10_3389_fimmu_2022_1046755
crossref_primary_10_1111_cei_13344
crossref_primary_10_1016_j_semcancer_2024_11_003
crossref_primary_10_3389_fcell_2021_694831
crossref_primary_10_3390_ijms20092258
crossref_primary_10_1016_j_isci_2023_108746
crossref_primary_10_3390_ijms22137016
crossref_primary_10_1016_j_exger_2017_07_002
crossref_primary_10_3389_fimmu_2017_00692
crossref_primary_10_1080_15412555_2023_2299104
crossref_primary_10_1038_s41577_019_0180_1
crossref_primary_10_1158_1078_0432_CCR_20_1420
crossref_primary_10_3389_fimmu_2023_1284293
crossref_primary_10_1083_jcb_202401112
crossref_primary_10_1016_j_clim_2022_109202
crossref_primary_10_1016_j_it_2016_09_002
crossref_primary_10_3389_fonc_2020_01671
crossref_primary_10_3390_vaccines9121392
crossref_primary_10_3390_vaccines5010005
crossref_primary_10_3390_cells10092435
crossref_primary_10_3389_fimmu_2016_00616
crossref_primary_10_1016_j_intimp_2024_111807
crossref_primary_10_1016_j_exger_2016_12_001
crossref_primary_10_3389_fimmu_2023_1233870
crossref_primary_10_1111_acel_13272
crossref_primary_10_1186_s12979_023_00394_0
crossref_primary_10_3390_ijms21124346
crossref_primary_10_1016_j_brainresbull_2024_111055
crossref_primary_10_1007_s11912_017_0619_0
crossref_primary_10_1111_cei_12836
crossref_primary_10_3389_fimmu_2025_1487318
crossref_primary_10_1684_ecn_2020_0441
crossref_primary_10_3389_fragi_2024_1436346
crossref_primary_10_1016_j_clim_2021_108685
crossref_primary_10_1016_j_it_2023_05_005
crossref_primary_10_3390_ijms252312550
crossref_primary_10_1016_j_lungcan_2024_107925
crossref_primary_10_1097_QAD_0000000000001441
crossref_primary_10_3390_cancers14041078
crossref_primary_10_1111_acel_13028
crossref_primary_10_3389_fimmu_2024_1338680
crossref_primary_10_3390_cancers15071927
crossref_primary_10_3389_fimmu_2023_1212100
crossref_primary_10_3389_fimmu_2018_00339
crossref_primary_10_1038_leu_2016_84
crossref_primary_10_3389_fimmu_2022_906355
crossref_primary_10_1371_journal_pone_0280851
crossref_primary_10_1172_jci_insight_120974
crossref_primary_10_18632_aging_205985
crossref_primary_10_1016_j_isci_2022_104202
crossref_primary_10_1016_j_semcancer_2024_12_001
crossref_primary_10_3389_fimmu_2020_583019
crossref_primary_10_1016_j_ccell_2020_05_004
crossref_primary_10_1038_s41598_024_80971_5
crossref_primary_10_3389_fimmu_2017_00778
crossref_primary_10_1002_eji_201546178
crossref_primary_10_1007_s00262_016_1803_z
crossref_primary_10_14336_AD_2024_0219
crossref_primary_10_1038_s41573_024_01126_9
crossref_primary_10_70401_acrt_2024_104
crossref_primary_10_1002_JLB_5MR0520_466R
crossref_primary_10_3390_biom13071085
crossref_primary_10_1016_j_critrevonc_2020_103036
crossref_primary_10_1016_j_arr_2022_101634
crossref_primary_10_1111_acel_12675
crossref_primary_10_1042_BST20150092
crossref_primary_10_1016_j_prp_2024_155534
crossref_primary_10_1016_j_exger_2018_01_005
crossref_primary_10_1016_j_esmoop_2022_100577
crossref_primary_10_31491_APT_2022_06_083
crossref_primary_10_1016_j_ejca_2021_11_024
crossref_primary_10_1111_acel_14300
crossref_primary_10_1186_s40425_018_0336_8
crossref_primary_10_1038_s41577_020_00454_2
crossref_primary_10_1189_jlb_3MA0717_283
crossref_primary_10_1007_s10522_023_10075_6
crossref_primary_10_1111_cei_12876
crossref_primary_10_1007_s10522_018_9771_7
crossref_primary_10_1002_mco2_70048
crossref_primary_10_3389_fimmu_2024_1360141
crossref_primary_10_1002_ijc_31813
crossref_primary_10_3389_fragi_2023_1202152
crossref_primary_10_1111_acel_14317
crossref_primary_10_1111_imr_13206
crossref_primary_10_3389_fragi_2021_719342
crossref_primary_10_3389_fimmu_2017_01960
Cites_doi 10.1084/jem.20100637
10.1038/nri2959
10.4049/jimmunol.1203267
10.1084/jem.194.12.1711
10.1016/j.virol.2004.11.028
10.1038/nature02118
10.1093/intimm/dxn123
10.1182/blood-2006-06-027060
10.1182/blood-2009-01-199588
10.1038/ni.1679
10.1128/JVI.77.8.4911-4927.2003
10.4049/jimmunol.175.12.8218
10.1038/nri2318
10.1073/pnas.0503095102
10.1038/nm0402-379
10.1016/S1097-2765(04)00256-4
10.1186/ar1905
10.1016/j.it.2009.03.013
10.1016/j.critrevonc.2013.08.002
10.1111/j.1365-2567.2010.03386.x
10.1007/s10875-010-9499-x
10.1111/j.1365-2567.2010.03345.x
10.1111/imm.12409
10.1016/S0264-410X(99)00502-2
10.4049/jimmunol.1301409
10.1016/j.cell.2012.01.003
10.1038/nature05115
10.1016/j.immuni.2007.09.006
10.1111/j.1365-2567.2011.03550.x
10.1038/nri1440
10.4049/jimmunol.178.12.7710
10.1242/jcs.019372
10.1186/1742-4933-5-6
10.1172/JCI75051
10.1038/ni1515
10.4049/jimmunol.175.12.8003
10.1084/jem.20072076
10.1111/j.1600-065X.2009.00767.x
10.1084/jem.20100643
10.1046/j.1365-2443.2003.00620.x
10.4049/jimmunol.0901522
10.1177/0091270009357433
10.1038/nri1254
10.1002/art.24266
10.1002/cyto.a.20643
10.1002/cyto.a.21015
10.1016/j.ejpain.2011.04.005
10.1111/j.1432-2277.2009.00927.x
10.4049/jimmunol.1100978
ContentType Journal Article
Copyright 2015 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim
2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Copyright_xml – notice: 2015 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim
– notice: 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
– notice: 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7T5
7TK
7TM
8FD
FR3
H94
K9.
M7N
P64
RC3
7X8
DOI 10.1002/eji.201445312
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
Neurosciences Abstracts
Nucleic Acids Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Genetics Abstracts
Technology Research Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
Nucleic Acids Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

Genetics Abstracts
CrossRef
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1521-4141
EndPage 1451
ExternalDocumentID 3677076741
25707450
10_1002_eji_201445312
EJI3292
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Biotechnology and Biological Sciences Research Council
– fundername: Medical Research Council
  grantid: MR/M003833/1
– fundername: Biotechnology and Biological Sciences Research Council
  grantid: BB/E019188/1
– fundername: Biotechnology and Biological Sciences Research Council
  grantid: BB/J006750/1
GroupedDBID ---
.3N
.55
.GA
.GJ
.HR
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
24P
31~
33P
3O-
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5GY
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEFU
ABEML
ABIJN
ABJNI
ABLJU
ABPVW
ABQWH
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACGFS
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AI.
AITYG
AIURR
AIWBW
AJBDE
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
AOETA
ASPBG
ATUGU
AUFTA
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMNLL
BMXJE
BNHUX
BROTX
BRXPI
BY8
CS3
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRSTM
DU5
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
G-S
G.N
GNP
GODZA
H.T
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
J5H
JPC
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M65
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MXFUL
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OHT
OIG
OK1
OVD
P2P
P2W
P2X
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RGB
RIWAO
RJQFR
ROL
RWI
RX1
SAMSI
SUPJJ
SV3
TEORI
UB1
UPT
V2E
VH1
W8V
W99
WBKPD
WHWMO
WIB
WIH
WIK
WIN
WJL
WOHZO
WQJ
WRC
WUP
WVDHM
WXSBR
X7M
XG1
XPP
XV2
Y6R
ZGI
ZXP
ZZTAW
~IA
~KM
~WT
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7T5
7TK
7TM
8FD
FR3
H94
K9.
M7N
P64
RC3
7X8
ID FETCH-LOGICAL-c4032-35c834396e7ead746cdce7e4f5bb1b175b539069e3c8cc49e4feecd121fd8aff3
IEDL.DBID DR2
ISSN 0014-2980
1521-4141
IngestDate Fri Jul 11 05:12:08 EDT 2025
Fri Jul 25 12:11:34 EDT 2025
Mon Jul 21 05:56:59 EDT 2025
Tue Jul 01 01:05:33 EDT 2025
Thu Apr 24 23:00:30 EDT 2025
Wed Jan 22 16:21:01 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Inhibitory receptors
Aging
T cells
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4032-35c834396e7ead746cdce7e4f5bb1b175b539069e3c8cc49e4feecd121fd8aff3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/eji.201445312
PMID 25707450
PQID 1679221964
PQPubID 986365
PageCount 11
ParticipantIDs proquest_miscellaneous_1680176395
proquest_journals_1679221964
pubmed_primary_25707450
crossref_primary_10_1002_eji_201445312
crossref_citationtrail_10_1002_eji_201445312
wiley_primary_10_1002_eji_201445312_EJI3292
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate May 2015
2015-05-00
2015-May
20150501
PublicationDateYYYYMMDD 2015-05-01
PublicationDate_xml – month: 05
  year: 2015
  text: May 2015
PublicationDecade 2010
PublicationPlace Germany
PublicationPlace_xml – name: Germany
– name: Weinheim
PublicationTitle European journal of immunology
PublicationTitleAlternate Eur J Immunol
PublicationYear 2015
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2005; 175
2005; 332
2004; 4
2011; 11
2008; 8
2009; 113
2008; 5
2011; 15
2008; 73
2007; 109
2007; 178
2000; 18
2009; 10
1989; 75
2012; 135
2005; 102
2003; 8
2007; 8
2003; 3
2013; 191
2013; 190
2014; 124
2006; 443
2007; 27
2009; 22
2009; 21
2010; 207
2009; 60
2002; 8
2011; 31
2006; 8
2008; 205
2011; 79
2012; 148
2008; 121
2014; 89
2011; 132
2003; 77
2009; 30
2003; 426
2001; 194
2002; 62
2004; 14
2010; 132
2009; 183
2014; 144
2009; 229
2011; 187
2010; 50
e_1_2_7_3_1
e_1_2_7_9_1
e_1_2_7_7_1
e_1_2_7_19_1
e_1_2_7_15_1
e_1_2_7_41_1
e_1_2_7_13_1
e_1_2_7_43_1
e_1_2_7_11_1
e_1_2_7_45_1
e_1_2_7_47_1
e_1_2_7_26_1
e_1_2_7_49_1
e_1_2_7_28_1
e_1_2_7_50_1
e_1_2_7_25_1
e_1_2_7_31_1
e_1_2_7_52_1
e_1_2_7_23_1
e_1_2_7_33_1
e_1_2_7_21_1
e_1_2_7_35_1
e_1_2_7_37_1
e_1_2_7_39_1
e_1_2_7_6_1
e_1_2_7_4_1
Valmori D. (e_1_2_7_5_1) 2002; 62
e_1_2_7_8_1
e_1_2_7_18_1
e_1_2_7_16_1
e_1_2_7_40_1
e_1_2_7_2_1
e_1_2_7_14_1
e_1_2_7_42_1
e_1_2_7_12_1
e_1_2_7_10_1
e_1_2_7_46_1
e_1_2_7_48_1
e_1_2_7_27_1
e_1_2_7_29_1
Monteiro M. (e_1_2_7_17_1) 2007; 109
e_1_2_7_51_1
e_1_2_7_30_1
e_1_2_7_24_1
e_1_2_7_32_1
e_1_2_7_22_1
e_1_2_7_34_1
e_1_2_7_20_1
e_1_2_7_36_1
e_1_2_7_38_1
Nagel J. E. (e_1_2_7_44_1) 1989; 75
References_xml – volume: 4
  start-page: 737
  year: 2004
  end-page: 743
  article-title: Will telomere erosion lead to a loss of T‐cell memory?
  publication-title: Nat. Rev. Immunol.
– volume: 175
  start-page: 8218
  year: 2005
  end-page: 8225
  article-title: Cytomegalovirus‐specific CD4+ T cells in healthy carriers are continuously driven to replicative exhaustion
  publication-title: J. Immunol.
– volume: 229
  start-page: 114
  year: 2009
  end-page: 125
  article-title: PD‐1 signaling in primary T cells
  publication-title: Immunol. Rev.
– volume: 426
  start-page: 194
  year: 2003
  end-page: 198
  article-title: A DNA damage checkpoint response in telomere‐initiated senescence
  publication-title: Nature
– volume: 178
  start-page: 7710
  year: 2007
  end-page: 7719
  article-title: The loss of telomerase activity in highly differentiated CD8+CD28‐CD27‐ T cells is associated with decreased Akt (Ser473) phosphorylation
  publication-title: J. Immunol.
– volume: 194
  start-page: 1711
  year: 2001
  end-page: 1719
  article-title: Cytokine‐driven proliferation and differentiation of human naive, central memory, and effector memory CD4(+) T cells
  publication-title: J. Exp. Med.
– volume: 73
  start-page: 975
  year: 2008
  end-page: 983
  article-title: Phenotype and function of human T lymphocyte subsets: consensus and issues
  publication-title: Cytometry A
– volume: 121
  start-page: 1046
  year: 2008
  end-page: 1053
  article-title: Telomerase does not counteract telomere shortening but protects mitochondrial function under oxidative stress
  publication-title: J. Cell Sci.
– volume: 60
  start-page: 335
  year: 2009
  end-page: 344
  article-title: Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double‐blind, methotrexate‐controlled study of patients with active rheumatoid arthritis
  publication-title: Arthritis Rheum.
– volume: 205
  start-page: 2111
  year: 2008
  end-page: 2124
  article-title: Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection
  publication-title: J. Exp. Med.
– volume: 135
  start-page: 355
  year: 2012
  end-page: 363
  article-title: Reversal of functional defects in highly differentiated young and old CD8 T cells by PDL blockade
  publication-title: Immunology
– volume: 191
  start-page: 3744
  year: 2013
  end-page: 3752
  article-title: IFN‐alpha inhibits telomerase in human CD8(+) T cells by both hTERT downregulation and induction of p38 MAPK signaling
  publication-title: J. Immunol.
– volume: 11
  start-page: 289
  year: 2011
  end-page: 295
  article-title: Are senescence and exhaustion intertwined or unrelated processes that compromise immunity?
  publication-title: Nat. Rev. Immunol.
– volume: 144
  start-page: 549
  year: 2014
  end-page: 560
  article-title: Multifunctional cytomegalovirus (CMV)‐specific CD8 T cells are not restricted by telomere‐related senescence in young or old adults
  publication-title: Immunology
– volume: 175
  start-page: 8003
  year: 2005
  end-page: 8010
  article-title: IL‐2 regulates perforin and granzyme gene expression in CD8+ T cells independently of its effects on survival and proliferation
  publication-title: J. Immunol.
– volume: 30
  start-page: 306
  year: 2009
  end-page: 312
  article-title: CD28(‐) T cells: their role in the age‐associated decline of immune function
  publication-title: Trends Immunol.
– volume: 10
  start-page: 29
  year: 2009
  end-page: 37
  article-title: Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
  publication-title: Nat. Immunol.
– volume: 8
  start-page: 512
  year: 2008
  end-page: 522
  article-title: Ageing and life‐long maintenance of T‐cell subsets in the face of latent persistent infections
  publication-title: Nat. Rev. Immunol.
– volume: 207
  start-page: 2187
  year: 2010
  end-page: 2194
  article-title: Targeting Tim‐3 and PD‐1 pathways to reverse T cell exhaustion and restore anti‐tumor immunity
  publication-title: J. Exp. Med.
– volume: 27
  start-page: 670
  year: 2007
  end-page: 684
  article-title: Molecular signature of CD8+ T cell exhaustion during chronic viral infection
  publication-title: Immunity
– volume: 8
  start-page: 131
  year: 2003
  end-page: 144
  article-title: Mitogen‐activated protein kinase p38 defines the common senescence‐signalling pathway
  publication-title: Genes Cells
– volume: 183
  start-page: 7063
  year: 2009
  end-page: 7072
  article-title: Interplay between chromatin remodeling and epigenetic changes during lineage‐specific commitment to granzyme B expression
  publication-title: J. Immunol.
– volume: 21
  start-page: 53
  year: 2009
  end-page: 62
  article-title: Correlation of effector function with phenotype and cell division after in vitro differentiation of naive MART‐1‐specific CD8+ T cells
  publication-title: Int. Immunol.
– volume: 132
  start-page: 104
  year: 2010
  end-page: 110
  article-title: Activation of p38 mitogen‐activated protein kinase is critical step for acquisition of effector function in cytokine‐activated T cells, but acts as a negative regulator in T cells activated through the T‐cell receptor
  publication-title: Immunology
– volume: 79
  start-page: 167
  year: 2011
  end-page: 174
  article-title: SPICE: exploration and analysis of post‐cytometric complex multivariate datasets
  publication-title: Cytometry A
– volume: 8
  start-page: 1246
  year: 2007
  end-page: 1254
  article-title: Upregulation of CTLA‐4 by HIV‐specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction
  publication-title: Nat. Immunol.
– volume: 50
  start-page: 1031
  year: 2010
  end-page: 1038
  article-title: A proof‐of‐concept and drug‐drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis
  publication-title: J. Clin. Pharmacol.
– volume: 332
  start-page: 16
  year: 2005
  end-page: 19
  article-title: Decreased perforin and granzyme B expression in senescent HIV‐1‐specific cytotoxic T lymphocytes
  publication-title: Virology
– volume: 22
  start-page: 1041
  year: 2009
  end-page: 1050
  article-title: The aging of the immune system
  publication-title: Transpl. Int.
– volume: 132
  start-page: 326
  year: 2011
  end-page: 339
  article-title: Cytomegalovirus infection induces the accumulation of short‐lived, multifunctional CD4+CD45RA+CD27+ T cells: the potential involvement of interleukin‐7 in this process
  publication-title: Immunology
– volume: 14
  start-page: 501
  year: 2004
  end-page: 513
  article-title: Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a)
  publication-title: Mol. Cell
– volume: 443
  start-page: 350
  year: 2006
  end-page: 354
  article-title: PD‐1 expression on HIV‐specific T cells is associated with T‐cell exhaustion and disease progression
  publication-title: Nature
– volume: 113
  start-page: 6619
  year: 2009
  end-page: 6628
  article-title: KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells
  publication-title: Blood
– volume: 31
  start-page: 137
  year: 2011
  end-page: 146
  article-title: Gain and loss of T cell subsets in old age—age‐related reshaping of the T cell repertoire
  publication-title: J. Clin. Immunol.
– volume: 102
  start-page: 8222
  year: 2005
  end-page: 8227
  article-title: The telomerase reverse transcriptase regulates chromatin state and DNA damage responses
  publication-title: Proc. Natl. Acad. Sci. USA
– volume: 207
  start-page: 2175
  year: 2010
  end-page: 2186
  article-title: Upregulation of Tim‐3 and PD‐1 expression is associated with tumor antigen‐specific CD8+ T cell dysfunction in melanoma patients
  publication-title: J. Exp. Med.
– volume: 190
  start-page: 5363
  year: 2013
  end-page: 5372
  article-title: Age‐associated increase of low‐avidity cytomegalovirus‐specific CD8+ T cells that re‐express CD45RA
  publication-title: J. Immunol.
– volume: 148
  start-page: 46
  year: 2012
  end-page: 57
  article-title: Aging, rejuvenation, and epigenetic reprogramming: resetting the aging clock
  publication-title: Cell
– volume: 75
  start-page: 286
  year: 1989
  end-page: 291
  article-title: Effect of age on the human high affinity interleukin 2 receptor of phytohaemagglutinin stimulated peripheral blood lymphocytes
  publication-title: Clin. Exp. Immunol.
– volume: 8
  start-page: 205
  year: 2006
  article-title: The p38 mitogen‐activated protein kinase signaling cascade in CD4 T cells
  publication-title: Arthritis Res. Ther.
– volume: 5
  start-page: 6
  year: 2008
  article-title: Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people
  publication-title: Immun. Ageing
– volume: 124
  start-page: 4004
  year: 2014
  end-page: 4016
  article-title: p38 signaling inhibits mTORC1‐independent autophagy in senescent human CD8+ T cells
  publication-title: J. Clin. Invest.
– volume: 62
  start-page: 1743
  year: 2002
  end-page: 1750
  article-title: Circulating tumor‐reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(‐) effector subset exerting ex vivo tumor‐specific cytolytic activity
  publication-title: Cancer Res.
– volume: 15
  start-page: 1040
  year: 2011
  end-page: 1048
  article-title: Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury
  publication-title: Eur. J. Pain
– volume: 3
  start-page: 931
  year: 2003
  end-page: 939
  article-title: Human CD8(+) T‐cell differentiation in response to viruses
  publication-title: Nat. Rev. Immunol.
– volume: 8
  start-page: 379
  year: 2002
  end-page: 385
  article-title: Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections
  publication-title: Nat. Med.
– volume: 77
  start-page: 4911
  year: 2003
  end-page: 4927
  article-title: Viral persistence alters CD8 T‐cell immunodominance and tissue distribution and results in distinct stages of functional impairment
  publication-title: J. Virol.
– volume: 18
  start-page: 1654
  year: 2000
  end-page: 1660
  article-title: Effect of aging on T lymphocyte activation
  publication-title: Vaccine
– volume: 187
  start-page: 2093
  year: 2011
  end-page: 2100
  article-title: Reversible senescence in human CD4+CD45RA+CD27‐ memory T cells
  publication-title: J. Immunol.
– volume: 89
  start-page: 140
  year: 2014
  end-page: 165
  article-title: Targeting the PD1/PD‐L1 axis in melanoma: biological rationale, clinical challenges and opportunities
  publication-title: Crit. Rev. Oncol. Hematol.
– volume: 109
  start-page: 2863
  year: 2007
  end-page: 2870
  article-title: Cartography of gene expression in CD8 single cells: novel CCR7‐subsets suggest differentiation independent of CD45RA expression
  publication-title: Blood
– ident: e_1_2_7_20_1
  doi: 10.1084/jem.20100637
– ident: e_1_2_7_15_1
  doi: 10.1038/nri2959
– ident: e_1_2_7_24_1
  doi: 10.4049/jimmunol.1203267
– ident: e_1_2_7_41_1
  doi: 10.1084/jem.194.12.1711
– ident: e_1_2_7_42_1
  doi: 10.1016/j.virol.2004.11.028
– ident: e_1_2_7_22_1
  doi: 10.1038/nature02118
– ident: e_1_2_7_12_1
  doi: 10.1093/intimm/dxn123
– volume: 109
  start-page: 2863
  year: 2007
  ident: e_1_2_7_17_1
  article-title: Cartography of gene expression in CD8 single cells: novel CCR7‐subsets suggest differentiation independent of CD45RA expression
  publication-title: Blood
  doi: 10.1182/blood-2006-06-027060
– ident: e_1_2_7_51_1
  doi: 10.1182/blood-2009-01-199588
– ident: e_1_2_7_26_1
  doi: 10.1038/ni.1679
– ident: e_1_2_7_30_1
  doi: 10.1128/JVI.77.8.4911-4927.2003
– ident: e_1_2_7_18_1
  doi: 10.4049/jimmunol.175.12.8218
– ident: e_1_2_7_3_1
  doi: 10.1038/nri2318
– ident: e_1_2_7_38_1
  doi: 10.1073/pnas.0503095102
– ident: e_1_2_7_40_1
  doi: 10.1038/nm0402-379
– ident: e_1_2_7_23_1
  doi: 10.1016/S1097-2765(04)00256-4
– ident: e_1_2_7_39_1
  doi: 10.1186/ar1905
– ident: e_1_2_7_14_1
  doi: 10.1016/j.it.2009.03.013
– ident: e_1_2_7_31_1
  doi: 10.1016/j.critrevonc.2013.08.002
– ident: e_1_2_7_8_1
  doi: 10.1111/j.1365-2567.2010.03386.x
– ident: e_1_2_7_11_1
  doi: 10.1007/s10875-010-9499-x
– ident: e_1_2_7_29_1
  doi: 10.1111/j.1365-2567.2010.03345.x
– ident: e_1_2_7_25_1
  doi: 10.1111/imm.12409
– ident: e_1_2_7_43_1
  doi: 10.1016/S0264-410X(99)00502-2
– ident: e_1_2_7_28_1
  doi: 10.4049/jimmunol.1301409
– ident: e_1_2_7_48_1
  doi: 10.1016/j.cell.2012.01.003
– ident: e_1_2_7_19_1
  doi: 10.1038/nature05115
– ident: e_1_2_7_49_1
  doi: 10.1016/j.immuni.2007.09.006
– ident: e_1_2_7_50_1
  doi: 10.1111/j.1365-2567.2011.03550.x
– ident: e_1_2_7_2_1
  doi: 10.1038/nri1440
– ident: e_1_2_7_10_1
  doi: 10.4049/jimmunol.178.12.7710
– ident: e_1_2_7_37_1
  doi: 10.1242/jcs.019372
– ident: e_1_2_7_16_1
  doi: 10.1186/1742-4933-5-6
– ident: e_1_2_7_9_1
  doi: 10.1172/JCI75051
– ident: e_1_2_7_32_1
  doi: 10.1038/ni1515
– ident: e_1_2_7_46_1
  doi: 10.4049/jimmunol.175.12.8003
– ident: e_1_2_7_7_1
  doi: 10.1084/jem.20072076
– volume: 75
  start-page: 286
  year: 1989
  ident: e_1_2_7_44_1
  article-title: Effect of age on the human high affinity interleukin 2 receptor of phytohaemagglutinin stimulated peripheral blood lymphocytes
  publication-title: Clin. Exp. Immunol.
– ident: e_1_2_7_36_1
  doi: 10.1111/j.1600-065X.2009.00767.x
– ident: e_1_2_7_21_1
  doi: 10.1084/jem.20100643
– volume: 62
  start-page: 1743
  year: 2002
  ident: e_1_2_7_5_1
  article-title: Circulating tumor‐reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(‐) effector subset exerting ex vivo tumor‐specific cytolytic activity
  publication-title: Cancer Res.
– ident: e_1_2_7_27_1
  doi: 10.1046/j.1365-2443.2003.00620.x
– ident: e_1_2_7_47_1
  doi: 10.4049/jimmunol.0901522
– ident: e_1_2_7_33_1
  doi: 10.1177/0091270009357433
– ident: e_1_2_7_6_1
  doi: 10.1038/nri1254
– ident: e_1_2_7_35_1
  doi: 10.1002/art.24266
– ident: e_1_2_7_4_1
  doi: 10.1002/cyto.a.20643
– ident: e_1_2_7_52_1
  doi: 10.1002/cyto.a.21015
– ident: e_1_2_7_34_1
  doi: 10.1016/j.ejpain.2011.04.005
– ident: e_1_2_7_45_1
  doi: 10.1111/j.1432-2277.2009.00927.x
– ident: e_1_2_7_13_1
  doi: 10.4049/jimmunol.1100978
SSID ssj0009659
Score 2.4838157
Snippet Immune enhancement is desirable in situations where decreased immunity results in increased morbidity. We investigated whether blocking the surface inhibitory...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1441
SubjectTerms Adult
Aged
Aged, 80 and over
Aging
Aging - immunology
Aging - pathology
CD8-Positive T-Lymphocytes - cytology
CD8-Positive T-Lymphocytes - immunology
CD8-Positive T-Lymphocytes - metabolism
Cell Differentiation - immunology
Cell Proliferation
Cellular Senescence - immunology
Cytokines - metabolism
Histones - metabolism
Humans
Immunologic Memory
Inhibitory receptors
Kinases
Leukocyte Common Antigens - metabolism
Lymphocytes
MAP Kinase Signaling System
p38 Mitogen-Activated Protein Kinases - antagonists & inhibitors
p38 Mitogen-Activated Protein Kinases - immunology
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Programmed Cell Death 1 Receptor - immunology
T cells
T-Lymphocyte Subsets - cytology
T-Lymphocyte Subsets - immunology
T-Lymphocyte Subsets - metabolism
Telomerase
Telomerase - metabolism
Young Adult
Title Blockade of PD‐1 or p38 MAP kinase signaling enhances senescent human CD8+ T‐cell proliferation by distinct pathways
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Feji.201445312
https://www.ncbi.nlm.nih.gov/pubmed/25707450
https://www.proquest.com/docview/1679221964
https://www.proquest.com/docview/1680176395
Volume 45
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ba9RAFB6koPhitd5Sq4wgvtS0ycxkkjzWXqiFlSIt9C3O5QTrSnZpdtH1yZ_gb_SXeE4mm7KKgvgWMmdIMjm3mTnzfYy90A6DsCxMnECqYuXRD5a1S2OdC2tAq7x0tDQwequPz9XJRXbR85zSWZiADzEsuJFldP6aDNzYdvcaNBQ-XlJlllKoReSDqV6LkqJ31_BRBJYXPLGKRVkkPcYm9t9d6b0ak35LNFfz1i7wHK2z98tXDvUm4535zO64r7-gOf7HN91ld_qklO8FLbrHbkCzwW4GmsrFBrs16jfg77MvrzH4jY0HPqn56cGPb99TPrniU1nw0d4pH182GBU5FYUYOufOoflAatXylnwqVYLyjhWQ7x8U2_wM-9POAZ8Sd1ANQRu5XXBPrqdxM06MyZ_Non3Azo8Oz_aP4568IXYqkXRCwBUSsx0NOSprrrTzDi9VnVmbWkxabCbLRJcgXeGcKrEFwPlUpLUvTF3Lh2ytmTTwmHGXK4MzeADQoEqtClBS47zXgPc-E3nEXi1_X-V6ZHMi2PhUBUxmUeG4VsO4RuzlID4NkB5_Etxa6kLVW3Zb0baVEARjFrHnQzPaJA2XaWAyJxmM--i4yyxij4IODU8i1sBcZUnEtjtN-PsrVIcnb6QoxeY_ST9ht_FeFuoyt9ja7GoOTzF3mtlnnYH8BGZ3EVk
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zb9QwEB6hIo4XjnIFChgJ8VLSJo7jJI-lh7alW1VoK_UtcpyJaLfKrrq7guWJn8Bv5JcwE2dTFgQS4i2SxzmcuWyPvw_gtbYUhKPU-AGGylcl-cGssqGvE1kY1CrJLC8N9I9070QdnManP53id_gQ3YIbW0bjr9nAeUF68wo1FM_PuDRLKVIjcsLXmdW7mVR9uAKQYrg854uVL7M0aFE26QabS92Xo9JvqeZy5tqEnr27YBYv7SpOhhuzabFhv_yC5_g_X3UP7rR5qdhyinQfrmG9CjccU-V8FW722z34B_D5HcW_oSlRjCpxvPP967dQjC7FOEpFf-tYDM9qCoyC60IMH3UXWH9kzZqICbtVLgYVDTGg2N5J18WA-vPmgRgzfVCFTiFFMRcle5_aTgWTJn8y88lDONnbHWz3_Ja_wbcqiPiQgE0jSng0JqSvidK2tHSpqrgowoLyliKOskBnGNnUWpVRC6ItQxlWZWqqKnoEK_WoxicgbKIMTeIRUaPKtEpRRZqmvgbLsoxl4sHbxf_LbQtuzhwbF7mDZZY5jWvejasHbzrxsUP1-JPg2kIZ8ta4JznvXEnJSGYevOqaySx5uEyNoxnLUOgn353FHjx2StQ9iYkDExUHHqw3qvD3V8h3D_Yjmcmn_yT9Em71Bv3D_HD_6P0zuE3tsSvTXIOV6eUMn1MqNS1eNNbyA3I8FXQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB6hIiouPAqUQAEjIS4lbR6O4xxLt6u2sNUKtVJvIbEnoizKrrq7guXET-A38kuYibOpFgQS4hbJ4zycbx62x98AvFCGnHCsCz_AUPrSkh3MKhP6Ko3KApVMM8NLA4MTdXgmj8-T87bOKZ-FcfwQ3YIba0Zjr1nBJ7bavSINxY8XnJklJaGIbPB1qQLNsO69u-KPYrY8Z4qlH2U6aEk26Qa7K91XndJvkeZq4Np4nv5teL98Z5dwMtqZz8od8_UXOsf_-Kg7cKuNSsWeg9FduIb1BtxwdSoXG7A-aHfg78GX1-T9RoVFMa7EsPfj2_dQjC_FJNZisDcUo4ua3KLgrJCCD7oLrD8wrqZiykaVU0FFUxZQ7Pf0tjil_rx1ICZcPKhCB0dRLoRl21ObmeCSyZ-LxfQ-nPUPTvcP_bZ6g29kEPMRAaNjCncUpoTWVCpjDV3KKinLsKSopUziLFAZxkYbIzNqQTQ2jMLK6qKq4gewVo9rfAjCpLKgKTwiKpSZkhplrGjiW6C1NolSD14tf19uWmpzrrDxKXekzFFO45p34-rBy0584jg9_iS4tcRC3qr2NOd9qyhiHjMPnnfNpJQ8XEWN4znLkOMny50lHmw6DHVP4rKBqUwCD7YbJPz9FfKD46M4yqJH_yT9DNaHvX7-9ujkzWO4Sc2Jy9HcgrXZ5RyfUBw1K582uvITOtQULA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Blockade+of+PD%E2%80%901+or+p38+MAP+kinase+signaling+enhances+senescent+human+CD8+%2B+T%E2%80%90cell+proliferation+by+distinct+pathways&rft.jtitle=European+journal+of+immunology&rft.au=Henson%2C+Sian+M.&rft.au=Macaulay%2C+Richard&rft.au=Riddell%2C+Natalie+E.&rft.au=Nunn%2C+Craig+J.&rft.date=2015-05-01&rft.issn=0014-2980&rft.eissn=1521-4141&rft.volume=45&rft.issue=5&rft.spage=1441&rft.epage=1451&rft_id=info:doi/10.1002%2Feji.201445312&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_eji_201445312
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-2980&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-2980&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-2980&client=summon